<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37488" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Box Warning</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Delong</surname>
            <given-names>Claire</given-names>
          </name>
          <aff>Kansas City University of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Claire Delong declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37488.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Boxed warnings (formerly&#x000a0;known as Black Box Warnings) are the highest safety-related warnings that medications can have assigned by the Food and Drug Administration. These warnings are intended to bring the consumer&#x02019;s attention to the major risks of the drug. Medications can have a&#x000a0;boxed warning added, taken away, or updated throughout their tenure on the market. Over 400 different medications currently have&#x000a0;boxed warnings.<xref ref-type="bibr" rid="article-37488.r1">[1]</xref></p>
        <p>Boxed warnings typically apply to a particular drug cohort rather than one specific drug; this is because, commonly, the severe risk is associated with the mechanism of action and its undesired effects on the body, therefore applying to several medications within a class.<xref ref-type="bibr" rid="article-37488.r2">[2]</xref></p>
      </sec>
      <sec id="article-37488.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Medications with boxed warnings associated with them may have adverse financial consequences as these warnings can affect the marketability of the drug and generate negative news reports.</p>
        <p>Clinicians must use their clinical judgment on whether or not to prescribe medications with these warnings to their patient's care.&#x000a0;Boxed warnings are not meant to be absolute contraindications for drugs, but instead, to bring the attention to the clinician and pharmacist on potential severe side effects.<xref ref-type="bibr" rid="article-37488.r3">[3]</xref><xref ref-type="bibr" rid="article-37488.r4">[4]</xref></p>
        <p>In rare instances, a drug may be the subject of a recall from the market. The most serious type of recall (Class I) is when the use of a medication may cause severe health detriments or even possible death.</p>
      </sec>
      <sec id="article-37488.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Examples of medications with&#x000a0;boxed warnings<xref ref-type="bibr" rid="article-37488.r5">[5]</xref><xref ref-type="bibr" rid="article-37488.r6">[6]</xref><xref ref-type="bibr" rid="article-37488.r7">[7]</xref><xref ref-type="bibr" rid="article-37488.r8">[8]</xref><xref ref-type="bibr" rid="article-37488.r9">[9]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluoroquinolone antimicrobials: increased risk of tendinitis and/or tendon rupture</p>
          </list-item>
          <list-item>
            <p>Rosiglitazone: increased risk of heart failure or myocardial infarction if the patient has current heart disease</p>
          </list-item>
          <list-item>
            <p>Selective serotonin reuptake inhibitors (SSRIs): increased risk of suicidal thinking and behavior in pediatric patients</p>
          </list-item>
          <list-item>
            <p>Celecoxib: cardiovascular and gastrointestinal risks</p>
          </list-item>
          <list-item>
            <p>Medroxyprogesterone: decreased bone density with long-term use</p>
          </list-item>
        </list>
        <p>Examples of medications with warnings that have been updated<xref ref-type="bibr" rid="article-37488.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Varenicline: the FDA removed the warning in 2009; original reports of depression, suicidal thoughts, and actions</p>
          </list-item>
        </list>
        <p>The Food and Drug Administration uses a program, i.e., MedWatch, that helps to track adverse events associated with medications. There is an online program accessible to clinicians and patients to enter the adverse effects of a medicine.<xref ref-type="bibr" rid="article-37488.r1">[1]</xref></p>
      </sec>
      <sec id="article-37488.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>The healthcare team, i.e., clinicians, nurses, and pharmacists, must work together to make sure that patients on pharmacotherapy correctly take their medications, e.g., ciprofloxacin, and importantly, to discuss any serious drug side effects they encounter, e.g., tendinitis, etc. This includes knowledge of any FDA-boxed warnings. A complete medication list for the patient is necessary before prescribing medications to prevent clinically significant drug interactions, and a pharmacist can perform medication reconciliation to answer any questions or address concerns other healthcare team members may have. [Level 5]</p>
      </sec>
      <sec id="article-37488.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37488&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37488">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37488/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37488">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37488.s6">
        <title>References</title>
        <ref id="article-37488.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bringing greater transparency to "black box" warnings.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>448</fpage>
            <page-range>448-51</page-range>
            <pub-id pub-id-type="pmid">21824055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panagiotou</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Contopoulos-Ioannidis</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Papanikolaou</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Ntzani</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Ioannidis</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Different black box warning labeling for same-class drugs.</article-title>
            <source>J Gen Intern Med</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>603</fpage>
            <page-range>603-10</page-range>
            <pub-id pub-id-type="pmid">21286838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Connor</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>FDA boxed warnings: how to prescribe drugs safely.</article-title>
            <source>Am Fam Physician</source>
            <year>2010</year>
            <month>Feb</month>
            <day>01</day>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>298</fpage>
            <page-range>298-303</page-range>
            <pub-id pub-id-type="pmid">20112888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Borgelt</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Black box warnings: what do they mean to pharmacists and patients.</article-title>
            <source>Consult Pharm</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>482</fpage>
            <page-range>482-92</page-range>
            <pub-id pub-id-type="pmid">22910129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanne</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>FDA adds "black box" warning label to fluoroquinolone antibiotics.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>Jul</month>
            <day>15</day>
            <volume>337</volume>
            <issue>7662</issue>
            <fpage>a816</fpage>
            <pub-id pub-id-type="pmid">18632714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanne</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>FDA places "black box" warning on antidiabetes drugs.</article-title>
            <source>BMJ</source>
            <year>2007</year>
            <month>Jun</month>
            <day>16</day>
            <volume>334</volume>
            <issue>7606</issue>
            <fpage>1237</fpage>
            <pub-id pub-id-type="pmid">17569906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kondro</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>FDA urges "black box" warning on pediatric antidepressants.</article-title>
            <source>CMAJ</source>
            <year>2004</year>
            <month>Oct</month>
            <day>12</day>
            <volume>171</volume>
            <issue>8</issue>
            <fpage>837</fpage>
            <page-range>837-8</page-range>
            <pub-id pub-id-type="pmid">15477614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenzer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke.</article-title>
            <source>BMJ</source>
            <year>2005</year>
            <month>Feb</month>
            <day>26</day>
            <volume>330</volume>
            <issue>7489</issue>
            <fpage>440</fpage>
            <pub-id pub-id-type="pmid">15731142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The FDA, contraceptive marketing approval and products liability litigation: Depo-Provera and the risk of osteoporosis.</article-title>
            <source>Food Drug Law J</source>
            <year>2013</year>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-35, i</page-range>
            <pub-id pub-id-type="pmid">24640465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37488.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammadi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Black-box warnings could be removed from varenicline.</article-title>
            <source>Lancet Respir Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>861</fpage>
            <pub-id pub-id-type="pmid">27742352</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
